RxDoctor Payments Data

Lauren Tafur

Nurse Practitioner · The Villages, FLNPI 1316903248

Payments from drug & device makers

$1,098in general payments, 2019–2025

Across 28 payments — averaging $39.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$426
  • Johnson & Johnson$208
  • Bayer$158
  • GSK$101
  • Exact Sciences$77
  • Pfizer$41
  • plus $88 from 5 others

What the payments were for

  • Food & beverage$1,098100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca5$426
Johnson & Johnson4$208
Bayer5$158
GSK1$101
Exact Sciences5$77
Pfizer2$41
Abbott2$27
Lundbeck LLC1$17
Amgen1$17
Novo Nordisk1$14
Biogen1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,098 in reported general payments places this provider in the 75th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$28,874
Medicare patients
165
Services billed
945

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban28$30,537
JardianceEmpagliflozin37$26,165
MounjaroTirzepatide19$23,347
OzempicSemaglutide12$10,839
Colesevelam Hcl38$4,824
JanuviaSitagliptin Phosphate13$3,742
Levothyroxine Sodium184$2,399
Epinephrine11$2,060
Montelukast Sodium114$1,939
Rosuvastatin Calcium100$1,567
Atorvastatin Calcium103$1,389
Mirtazapine29$1,049
SynthroidLevothyroxine Sodium32$999
Fluticasone Propionate51$968
Trazodone Hcl47$898

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$41$30,53728 claims
Novo NordiskOzempic$14$10,83912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in The Villages

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →